C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy.
about
Biological drugs in Guillain-Barré Syndrome: an update.Guillain-Barré syndrome: a century of progress.Complement in the pathogenesis of Alzheimer's disease.Nonclinical Development of ANX005: A Humanized Anti-C1q Antibody for Treatment of Autoimmune and Neurodegenerative Diseases.Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases
P2860
C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
C1q-targeted inhibition of the ...... acute motor axonal neuropathy.
@en
type
label
C1q-targeted inhibition of the ...... acute motor axonal neuropathy.
@en
prefLabel
C1q-targeted inhibition of the ...... acute motor axonal neuropathy.
@en
P2093
P2860
P50
P1476
C1q-targeted inhibition of the ...... acute motor axonal neuropathy.
@en
P2093
Hugh J Willison
Jennifer A Barrie
Koichi Furukawa
Sethu Sankaranarayanan
Simon N Fewou
Ted A Yednock
P2860
P2888
P356
10.1186/S40478-016-0291-X
P577
2016-03-02T00:00:00Z
P5875
P6179
1010907502